SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 197.01-2.9%Dec 1 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bat5454 who wrote (14899)2/12/1998 4:32:00 PM
From: Andrew C.R. Biddle  Read Replies (1) of 32384
 
A good article in the street.com about asthma mentioned LGND.

A new class, and one that is likely to perform the best, attacks the
most fundamental of the mediators, IL-4. IL-4 is the first mediator to
be released, and it starts the chain of events that ultimately results
in the symptoms of asthma. Inhibiting or circumventing IL-4 will be
critical. From this perspective, I give a thumbs up to Glaxo
Wellcome, Ligand (LGND:Nasdaq) and Immunex (IMNX:Nasdaq).
Of these three, Immunex is the furthest along in the development
process, and its data, to be presented at the American Association
of Allergy, Asthma and Immunology conference this March, will be
most interesting.

Andrew
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News